RxDoctor Payments Data

Navneet Majhail, MD

Hematology · Nashville, TNNPI 1053342154

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $37,010 of the $57,973 with a category attached, or 63.8%. Incyte Corporation accounts for 63.9% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2020 at $18,560 and has fallen 90.1% since, to $1,837 in 2025.

$57,973in general payments, 2019–2025

Across 32 payments — averaging $1811.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Incyte Corporation$37K
  • Mallinckrodt Enterprises LLC$18K
  • National Marrow Donor Program$2K
  • Gilead$245
  • Mckesson Sourcing Services, Inc.$231
  • AstraZeneca$191
  • plus $275 from 5 others
$14,000in research payments, 2019–2025

Across 2 payments — averaging $7000.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bristol Myers Squibb$13K
  • National Marrow Donor Program$1K

What the payments were for

  • Consulting fees$37,01064%
  • Speaking & faculty fees$6,88012%
  • Travel & lodging$12,51422%
  • Food & beverage$1,4943%
  • Gifts$750%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,973 in reported general payments places this provider in the 85th percentile of 23 hematology providers in Tennessee.

See all hematology providers in Tennessee

Medicare billing

Part B allowed, 2024
$46,045
Medicare patients
69
Services billed
409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →